This paper analyzes the decision of a health authority to implement personalized medicine. We consider a model in which the health authority has three possibilities. It can apply either the same treatment (a standard or a new treatment) to the whole population or implement personalized medicine, i.e., use genetic information to offer the most suitable treatment to each patient. We first characterize the drug reimbursement contract of a firm producing a new treatment with a companion genetic test when the firm can undertake an effort to improve drug quality. Then, we determine the conditions under which personalized medicine should be implemented when this effort is observable and when it is not. Finally, we show how the unobservability of effort affects the conditions under which the health authority implements personalized medicine.

本文分析了卫生当局实施个性化医疗的决定。我们考虑一个模型，其中卫生当局有三种可能性。它可以将相同的治疗（标准或新治疗）应用于整个人群，也可以实施个性化医疗，即利用遗传信息为每个患者提供最合适的治疗。当公司可以努力提高药物质量时，我们首先描述了一个公司的药物报销合同，该公司通过伴随基因测试生产新的治疗方法。然后，我们确定在哪些情况下应该实施个性化医疗，何时可以观察到这种努力，何时不可观察。最后，我们展示了努力的不可观察性如何影响卫生当局实施个性化医疗的条件。